BioSpace News Archive

Itamar Medical Ltd. announced that its flagship WatchPAT™300 Home Sleep Apnea Testing device has been granted PMDA approval for use in the Japanese market, effective September 14, 2020.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.

Merck, known as MSD outside the United States and Canada, will hold its third-quarter 2020 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, October 27.

Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces that it has received DKK 4.8 million in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses program.

Researchers Will Present Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine, and Phase 1/1b Data for MK-8507, an Investigational NNRTI for the Treatment of HIV-1 Infection

Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020.

Replimune Group Inc. announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.

Plus Therapeutics, Inc., announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology Annual Meeting being held virtually on November 19-21, 2020.

VYNE Therapeutics Inc. announced that its novel ZILXI™ topical foam, 1.5% is available as of today, October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults.

Vascular Graft Solutions Ltd., an Israel-based innovative commercial-stage medical device company, announced that the China National Medical Products Administration granted Innovative Medical Device Designation for VEST™, an external stent for vein grafts in coronary artery bypass surgery.